Skip to main content
. 2017 Jul 28;8(47):82609–82620. doi: 10.18632/oncotarget.19664

Figure 1. Serial splenic injection isolates a prometastatic subclone of neuroblastoma (BE(2)-C/LM2).

Figure 1

(A) Schematic representation of the in vivo selection model used to isolate aggressive sub-clones of neuroblastoma cells from murine liver metastatic foci. (B) Serial in vivo bioluminescent imaging demonstrates enhanced metastatic burden in mice injected with the BE(2)-C/LM2 cells as compared to parental BE(2)-C/Luc cells. (C) BE(2)-C/LM2 liver explant weights were significantly greater than livers isolated from mice injected with BE(2)-C/Luc cells. (D) No differences in spleen weights were noted between groups (p=0.76). (E, F) Explant bioluminescence demonstrates enhanced neuroblastoma tumor burden in the liver of mice injected with BE(2)-C/LM2 cells (mean ± SEM; *=p<0.001).